Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)

NCT01416311 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01416311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01416311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
December 21, 2010
Completion date
October 16, 2020
Enrollment
5,797 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

purpura, thrombocytopaenic, idiopathic